Once-Weekly Semaglutide in Adolescents with Obesity

What Was Tested

This randomized controlled trial paper looks at Semaglutide.

Who Took Part

The age groups tagged for this paper are children and teenagers.

In this double-blind, parallel-group, randomized, placebo-controlled trial, the researchers enrolled adolescents (12 to <18 years of age) with obesity (a body-mass index [BMI] in the 95th percentile or higher) or with overweight (a BMI in the 85th percentile or higher) and at least one weight-related coexisting condition.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and parallel-group.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.

A placebo (an inactive look-alike) gave the Semaglutide group a baseline to be compared against.

The Semaglutide group and the comparison group ran side by side rather than switching.

What Was Measured

PubMed files the paper under topics including Pediatric Obesity, Weight Loss, Healthy Lifestyle, Body Mass Index, Anti-Obesity Agents, Administration, Cutaneous and Glucagon-Like Peptide-1 Receptor Agonists.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide.

Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (The New England journal of medicine), a journal based in United States.

More context: the Semaglutide compound page, all human trials.